Mark Chalmers PhD was a Principal at CBPartners.
Connect with Mark Chalmers PhD
After years of anticipation, CAR-Ts (chimeric antigen receptor–T-cells) finally made the transition from being promising future therapies, to breakthrough marketed products in 2017. CBPartners' Cell and Gene Therapy Center of Excellence explores the challenges that CAR-T combination therapies face.
In an unprecedented move, the UK's National Institute for Health and Care Excellence (NICE) recently recommended NHS funding of GSK's gene therapy STRIMVELIS™ for an ultra-orphan immunodeficiency disorder ADA-SCID1 – also dubbed the “Bubble Baby Syndrome” priced at EUR 594,000. Given NICE’s resistance to such high per-patient therapy costs, CBPartners investigates how GSK was able to defend the value positioning of the STRIMVELIS™ to NICE.
In April 2017, AIFA (Agenzia Italiana del Farmaco, Italian Medicines Agency) released a new algorithm to assess and evaluate the level of innovativeness of new drugs aimed to get reimbursement by the SSN (Sistema Sanitario Nazionale, National Health System) through the EUR 1 billion fund made available by the Italian MoH (Ministero della Salute, Ministry of Health) for innovative therapies. CBPartners investigates the impact that this has.